Microbot Medical Inc. Expands Global IP Portfolio as Patent in India Covering the Company’s TipCAT™ Technology Platform i...
September 15 2017 - 7:00AM
Microbot Medical Inc. (Nasdaq:MBOT), a medical device company
specializing in the design and development of transformational
micro-robotic medical technologies, today announced that
Intellectual Property India granted patent No. 286765, covering the
Company’s TipCAT™ technology platform.
“We continue to strengthen and expand our IP
portfolio,” commented Harel Gadot, Chief Executive Officer,
President, and Chairman. “As a pioneer in micro-robotic surgery,
this will allow us to add value to our assets as it is expected to
enhance our ability to access global markets and create additional
competitive advantages and barriers to entry. India is a large and
emerging market and we believe having a strong IP presence in this
market further builds shareholder value. In addition to
India, the TipCAT™ technology platform patent has already been
granted in the largest markets such as the U.S., China, Europe and
several other markets, which we believe continues to show the
strength of our IP assets. With this specific IP, our
objective is to leverage the TipCAT platform to develop multiple
products that address serious unmet needs in multiple medical
applications.”
Globally, the Company now has 23 patents which
are already issued and an additional 13 patent applications pending
worldwide. The Company’s patents cover its ViRob™ and TipCAT™
technology platforms.
About Microbot Medical, Inc.
Microbot, which was founded in 2010 and
commenced operations in 2011, became a NASDAQ listed company on
November 28, 2016. The Company specializes in transformational
micro-robotic medical technologies leveraging the natural and
artificial lumens within the human body. Microbot’s current
platforms, ViRob™ and TipCAT™, are comprised of two highly advanced
micro-robotic technologies, from which the Company is currently
developing its first two product candidates: the Self Cleaning
Shunt, or SCS™, for the treatment of hydrocephalus and Normal
Pressure Hydrocephalus, or NPH; and a self-propelling,
semi-disposable endoscope that is being developed initially for use
in colonoscopy procedures. Further information about Microbot
Medical is available at http://www.microbotmedical.com.
The ViRob™ technology is a revolutionary
autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to
navigate and crawl in different spaces within the human body,
including blood vessels, the digestive tract and the respiratory
system. Its unique structure gives it the ability to move in
tight spaces and curved passages as well as the ability to remain
within the human body for prolonged time. To learn more about
ViRob™ please visit
http://www.microbotmedical.com/technology/virob/.
TipCAT™ is a transformational self-propelled,
flexible, and semi-disposable endoscope providing see & treat
capabilities within tubular lumens in the human body such as the
colon, blood vessels, and the urinary tract. Its locomotion
mechanism is perfectly suitable to navigate and crawl through
natural & artificial tubular lumens, applying the minimal
necessary pressure to achieve the adequate friction required for
gentle, fast, and safe advancement within the human body. To
learn more about TipCAT™ visit
http://www.microbotmedical.com/technology/tipcat/.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects” and “estimates”) should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials
or regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Microbot
Medical Inc. particularly those mentioned in the cautionary
statements found in Microbot Medical Inc.’s filings with the
Securities and Exchange Commission. Microbot Medical disclaims any
intent or obligation to update these forward-looking
statements.
Investor Contacts:
Analysts and Institutional InvestorsMichael
PolyviouEVC Groupmpolyviou@evcgroup.com646-445-4800
Individual InvestorsJeremy RoeIntegra
Consulting Group llcjeremy@integracg.net(925) 262-8305
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024